At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 100 enrolled
Drug / intervention
68Ga-DOTATATEdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
In Brief
A Early Phase 1 clinical trial evaluating 68Ga-DOTATATE for Neuroendocrine Tumors. Completed, enrolled 100 participants across 1 site.
Detailed Summary
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartAug 2013
Primary CompletionJun 2017
TodayJul 2026
First PostedJun 10, 2013
Enrollment StartAug 26, 2013
Primary CompletionJun 16, 2017
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.1 years ago
Interventions
68Ga-DOTATATEdrug
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.